Antiplatelet therapy: Targeting the TxA2 pathway

Journal of Cardiovascular Translational Research

Volumn 7, Issue 1, 2014, Pages 29-38

  Fontana, P ^a,b   Zufferey, A ^a,b   Daali, Y ^a   Reny, J L ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Aspirin; Atherosclerosis; Platelet; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EV 077; NONSTEROID ANTIINFLAMMATORY AGENT; OZAGREL; PARACETAMOL; PICOTAMIDE; PLACEBO; RAMATROBAN; RIDOGREL; SERATRODAST; STREPTOKINASE; TERUTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE; TRIFLUSAL; TRIPLION; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ALLERGIC RHINITIS; ANTICOAGULANT THERAPY; ARTICLE; ASTHMA; BRAIN ISCHEMIA; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PREECLAMPSIA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS THROMBOEMBOLISM;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SIGNAL TRANSDUCTION; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 84896738120     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9529-1     Document Type: Article

References (80)

1. Hansson, G. K., Robertson, A. K., & Soderberg-Naucler, C. (2006). Inflammation and atherosclerosis. Annual Review of Pathology, 1, 297-329. doi: 10.1146/annurev.pathol.1.110304.100100.
2. Libby, P. (2012). Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2045-2051. doi: 10.1161/ATVBAHA.108. 179705.
3. Coppinger, J. A., & Maguire, P. B. (2007). Insights into the platelet releasate. Current Pharmaceutical Design, 13(26), 2640-2646.
4. Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685-1695.
5. Kirkby, N. S., Leadbeater, P. D., Chan, M. V., Nylander, S., Mitchell, J. A., & Warner, T. D. (2011). Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis, 9(10), 2103-2105. doi: 10.1111/j.1538-7836.2011.04453.x.
6. Armstrong, P. C., Leadbeater, P. D., Chan, M. V., Kirkby, N. S., Jakubowski, J. A., Mitchell, J. A., et al. (2011). In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis, 9(3), 552-561. doi: 10.1111/j.1538-7836.2010.04160.x.
7. Maclouf, J., Folco, G., & Patrono, C. (1998). Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thrombosis and Haemostasis, 79(4), 691-705.
8. Hamberg, M., Svensson, J., & Samuelsson, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 2994-2998.
9. Smyth, E. M. (2010). Thromboxane and the thromboxane receptor in cardiovascular disease. Journal of Clinical Lipidology, 5(2), 209-219. doi: 10.2217/CLP.10.11.
10. Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer and Metastasis Reviews, 30(3-4), 397-408. doi: 10.1007/s10555-011-9297-9.
11. Sakariassen, K. S., Alberts, P., Fontana, P., Mann, J., Bounameaux, H., & Sorensen, A. S. (2009). Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiology, 5(5), 479-493. doi: 10.2217/fca.09.33.
12. Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., et al. (2002). Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7634-7639. doi: 10.1073/pnas.112202999.
13. McAdam, B. F., Mardini, I. A., Habib, A., Burke, A., Lawson, J. A., Kapoor, S., et al. (2000). Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. The Journal of Clinical Investigation, 105(10), 1473-1482. doi: 10.1172/JCI9523.
14. Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13926-13931. doi: 10.1073/pnas.162468699.
15. Botting, R., & Ayoub, S. S. (2005). COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 72(2), 85-87. doi: 10.1016/j.plefa.2004.10.005.
16. Capra, V., Back, M., Barbieri, S. S., Camera, M., Tremoli, E., & Rovati, G. E. (2013). Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Medicinal Research Reviews, 33(2), 364-438. doi: 10.1002/med.21251.
17. Audoly, L. P., Rocca, B., Fabre, J. E., Koller, B. H., Thomas, D., Loeb, A. L., et al. (2000). Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation, 101(24), 2833-2840.
18. Narumiya, S. (1994). Prostanoid receptors. Structure, function, and distribution. Annals of the New York Academy of Sciences, 744, 126-138.
19. Nusing, R. M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K., & Narumiya, S. (1993). Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. The Journal of Biological Chemistry, 268(33), 25253-25259.
20. Unoki, M., Furuta, S., Onouchi, Y., Watanabe, O., Doi, S., Fujiwara, H., et al. (2000). Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Human Genetics, 106(4), 440-446.
21. Fontana, P., Gandrille, S., Remones, V., Dupont, A., Reny, J. L., Aiach, M., et al. (2006). Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thrombosis and Haemostasis, 96(3), 356-360.
22. Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., et al. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617-620.
23. Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C., & Ware, J. A. (1994). Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. The Journal of Biological Chemistry, 269(30), 19256-19261.
24. Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M., & Narumiya, S. (1996). Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. The Journal of Clinical Investigation, 97(4), 949-956.
25. Habib, A., FitzGerald, G. A., & Maclouf, J. (1999). Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. The Journal of Biological Chemistry, 274(5), 2645-2651.
26. Nakahata, N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology and Therapeutics, 118(1), 18-35. doi: 10.1016/j.pharmthera.2008.01.001.
27. Patrono, C. (1994). Aspirin as an antiplatelet drug. The New England Journal of Medicine, 330(18), 1287-1294.
28. Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., et al. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10(7), 1220-1230. doi: 10.1111/j.1538-7836.2012.04723.x.
29. Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., et al. (2012). Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood, 119(15), 3595-3603. doi: 10.1182/blood-2011-06-359224.
30. Davi, G., Santilli, F., & Vazzana, N. (2012). Thromboxane receptors antagonists and/or synthase inhibitors. Handbook of Experimental Pharmacology, 210, 261-286. doi: 10.1007/978-3-642-29423-5-11.
31. Rolin, S., Masereel, B., & Dogne, J. M. (2006). Prostanoids as pharmacological targets in COPD and asthma. European Journal of Pharmacology, 533(1-3), 89-100. doi: 10.1016/j.ejphar.2005.12.058.
32. Zhang, J., Yang, J., Chang, X., Zhang, C., Zhou, H., & Liu, M. (2012). Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurological Research, 34(4), 346-353. doi: 10.1179/1743132812Y.0000000022.
33. FitzGerald, G. A., Reilly, I. A., & Pedersen, A. K. (1985). The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation, 72(6), 1194-1201.
34. Cayatte, A. J., Du, Y., Oliver-Krasinski, J., Lavielle, G., Verbeuren, T. J., & Cohen, R. A. (2000). The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 20(7), 1724-1728.
35. Viles-Gonzalez, J. F., Fuster, V., Corti, R., Valdiviezo, C., Hutter, R., Corda, S., et al. (2005). Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition - a magnetic resonance imaging study. European Heart Journal, 26(15), 1557-1561. doi: 10.1093/eurheartj/ehi175.
36. Gaussem, P., Reny, J. L., Thalamas, C., Chatelain, N., Kroumova, M., Jude, B., et al. (2005). The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. Journal of Thrombosis and Haemostasis, 3(7), 1437-1445.
37. Fiessinger, J. N., Bounameaux, H., Cairols, M. A., Clement, D. L., Coccheri, S., Fletcher, J. P., et al. (2010). Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. Journal of Thrombosis and Haemostasis, 8(11), 2369-2376. doi: 10.1111/j.1538-7836.2010. 04020.x.
38. Bal Dit Sollier, C., Crassard, I., Simoneau, G., Bergmann, J. F., Bousser, M. G., & Drouet, L. (2009). Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovascular Diseases, 28(5), 505-513. doi: 10.1159/000236915.
39. Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K. M., et al. (2011). Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet, 377(9782), 2013-2022. doi: 10.1016/S0140-6736(11)60600-4.
40. Meadows, T. A., & Bhatt, D. L. (2007). Clinical aspects of platelet inhibitors and thrombus formation. Circulation Research, 100(9), 1261-1275. doi: 10.1161/01.RES.0000264509.36234.51.
41. The Ridogrel Versus Aspirin Patency Trial (RAPT). (1994). Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation, 89(2), 588-595.
42. Neri Serneri, G. G., Coccheri, S., Marubini, E., & Violi, F. (2004). Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European Heart Journal, 25(20), 1845-1852.
43. Fontana, P., & Reny, J. L. (2007). New antiplatelet strategies in atherothrombosis and their indications. European Journal of Vascular and Endovascular Surgery, 34(1), 10-17.
44. Fontana, P., Alberts, P., Sakariassen, K. S., Bounameaux, H., Meyer, J. P., & Santana Sorensen, A. (2011). The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Journal of Thrombosis and Haemostasis. doi: 10.1111/j.1538-7836.2011.04446.x.
45. Tello-Montoliu, A., Rollini, F., Desai, B., Pasqualino, G., Patel, R., Sorensen, A. S., et al. (2012). Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. Journal of Thrombosis and Thrombolysis, 34(3), 297-299. doi: 10.1007/s11239-012-0795-6.
46. Richardson, A., Sakariassen, K. S., Meyer, J. P., Alberts, P., & Sorensen, A. S. (2013). Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. European Journal of Clinical Pharmacology, 69(3), 459-465. doi: 10.1007/s00228-012-1348-9.
47. Rollini, F., Tello-Montoliu, A., Patel, R., Darlington, A., Wilson, R. E., Franchi, F., et al. (2013). Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Journal of Thrombosis and Thrombolysis. doi: 10.1007/s11239-013-0979-8.
48. Sakariassen, K. S., Femia, E. A., Daray, F. M., Podda, G. M., Razzari, C., Pugliano, M., et al. (2012). EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Thrombosis Research, 130(5), 746-752. doi: 10.1016/j.thromres.2012.08.309.
49. Elwood, P. C., Cochrane, A. L., Burr, M. L., Sweetnam, P. M., Williams, G., Welsby, E., et al. (1974). A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. British Medical Journal, 1(5905), 436-440.
50. Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blomstrom-Lundqvist, C., Borger, M. A., et al. (2012). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33(20), 2569-2619. doi: 10.1093/eurheartj/ehs215.
51. Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849-1860. doi: 10.1016/S0140-6736(09) 60503-1.
52. Fowkes, F. G., Price, J. F., Stewart, M. C., Butcher, I., Leng, G. C., Pell, A. C., et al. (2010). Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA, 303(9), 841-848. doi: 10.1001/jama.2010.221.
53. Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. (2012). European guidelines on cardiovascular disease prevention in clinical practice (version, 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal, 33(13), 1635-1701. doi: 10.1093/eurheartj/ehs092.
54. U.S. Preventive Services Task Force. (2009). Aspirin for the prevention of cardiovascular disease: recommendation statement. Annals of Internal Medicine, 150(6), 396-404.
55. De Berardis, G., Sacco, M., Strippoli, G. F., Pellegrini, F., Graziano, G., Tognoni, G., et al. (2009). Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 339, b4531. doi: 10.1136/bmj.b4531.
56. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31-41. doi: 10.1016/S0140-6736(10)62110-1.
57. Brighton, T. A., Eikelboom, J. W., Mann, K., Mister, R., Gallus, A., Ockelford, P., et al. (2012). Low-dose aspirin for preventing recurrent venous thromboembolism. The New England Journal of Medicine, 367(21), 1979-1987. doi: 10.1056/NEJMoa1210384.
58. Helgason, C. M., Tortorice, K. L., Winkler, S. R., Penney, D. W., Schuler, J. J., McClelland, T. J., et al. (1993). Aspirin response and failure in cerebral infarction. Stroke, 24(3), 345-350.
59. Michelson, A. D., Cattaneo, M., Eikelboom, J. W., Gurbel, P., Kottke-Marchant, K., Kunicki, T. J., et al. (2005). Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 3(6), 1309-1311.
60. Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., & Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis. The New England Journal of Medicine, 353(22), 2373-2383.
61. Hovens, M. M., Snoep, J. D., Eikenboom, J. C., van der Bom, J. G., Mertens, B. J., & Huisman, M. V. (2007). Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. American Heart Journal, 153(2), 175-181.
62. Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., & Yusuf, S. (2002). Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105(14), 1650-1655.
63. Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G., & Huisman, M. V. (2007). Association of laboratory-defined aspirin resistance with a higer risk of recurrent cardiovascular events. A systematic review and meta-analysis. Archives of Internal Medicine, 167(15), 1593-1599.
64. Reny, J. L., De Moerloose, P., Dauzat, M., & Fontana, P. (2008). Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 6(3), 444-450. doi: 10.1111/j.1538-7836.2008.02897. x.
65. Reny, J. L., Berdague, P., Poncet, A., Barazer, I., Nolli, S., Fabbro-Peray, P., et al. (2012). Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events Study. Circulation, 125(25), 3201-3210. doi: 10.1161/CIRCULATIONAHA.111.085464.
66. Pettersen, A. A., Seljeflot, I., Abdelnoor, M., & Arnesen, H. (2012). High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). Journal of the American Heart Association, 1(3), e000703. doi: 10.1161/JAHA.112.000703.
67. Stone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F. J., Metzger, D. C., et al. (2013). Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 382(9892), 614-623. doi: 10.1016/S0140-6736(13)61170-8.
68. Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J. L., Ueno, M., Kodali, M., et al. (2011). Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circulation. Cardiovascular Interventions, 4(2), 180-187. doi: 10.1161/CIRCINTERVENTIONS.110.960187.
69. Faraday, N., Yanek, L. R., Mathias, R., Herrera-Galeano, J. E., Vaidya, D., Moy, T. F., et al. (2007). Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation, 115(19), 2490-2496.
70. Kunicki, T. J., Williams, S. A., & Nugent, D. J. (2012). Genetic variants that affect platelet function. Current Opinion in Hematology, 19(5), 371-379. doi: 10.1097/MOH.0b013e3283567526.
71. Johnson, A. D., Yanek, L. R., Chen, M. H., Faraday, N., Larson, M. G., Tofler, G., et al. (2010). Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nature Genetics, 42(7), 608-613. doi: 10.1038/ng.604.
72. Zimmerman, G. A., & Weyrich, A. S. (2008). Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3), s17-s24. doi: 10.1161/ATVBAHA.107.160218.
73. Kondkar, A. A., Bray, M. S., Leal, S. M., Nagalla, S., Liu, D. J., Jin, Y., et al. (2010). VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. Journal of Thrombosis and Haemostasis, 8(2), 369-378. doi: 10.1111/j.1538-7836.2009.03700.x.
74. Edelstein, L. C., & Bray, P. F. (2011). MicroRNAs in platelet production and activation. Blood, 117(20), 5289-5296. doi: 10.1182/blood-2011- 01-292011.
75. Nagalla, S., Shaw, C., Kong, X., Kondkar, A. A., Edelstein, L. C., Ma, L., et al. (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189-5197. doi: 10.1182/blood-2010-09- 299719.
76. Burkhart, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L., et al. (2012). The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 120(15), e73-e82. doi: 10.1182/blood-2012-04-416594.
77. Mateos-Caceres, P. J., Macaya, C., Azcona, L., Modrego, J., Mahillo, E., Bernardo, E., et al. (2010). Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thrombosis and Haemostasis, 103(1), 160-170. doi: 10.1160/TH09-05-0290.
78. Lopez-Farre, A. J., Mateos-Caceres, P. J., Sacristan, D., Azcona, L., Bernardo, E., de Prada, T. P., et al. (2007). Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. Journal of Proteome Research, 6(7), 2481-2487. doi: 10.1021/pr060600i.
79. Bensimon, A., Heck, A. J., & Aebersold, R. (2012). Mass spectrometry-based proteomics and network biology. Annual Review of Biochemistry, 81, 379-405. doi: 10.1146/annurev-biochem-072909-100424.
80. Zufferey, A., Ibberson, M., Reny, J. L., Xenarios, I., Sanchez, J. C., & Fontana, P. (2013). Unraveling modulators of platelet reactivity in cardiovascular patients using omics strategies: towards a network biology paradigm. Translational Proteomics, 1(1), 25-37.